Published in PLoS One on February 12, 2016
mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res (2017) 0.75
mTOR signaling in growth control and disease. Cell (2012) 29.21
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
TOR, a central controller of cell growth. Cell (2000) 10.41
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med (2008) 9.64
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol (2000) 2.86
Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell (2014) 2.68
Common corruption of the mTOR signaling network in human tumors. Oncogene (2008) 2.60
JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell (2012) 2.34
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22
Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol (2005) 2.00
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene (2006) 1.72
Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell (2006) 1.62
Rapamycin: one drug, many effects. Cell Metab (2014) 1.41
Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal (2014) 1.37
Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One (2010) 1.36
Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res (2006) 1.36
mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets (2008) 1.33
Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol (2010) 1.33
Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol (2011) 1.27
Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene (2006) 1.25
Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene (2009) 1.25
Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis (2008) 1.24
Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem (2002) 1.22
Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol (2008) 1.21
Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids (2010) 1.20
Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol Cell Biol (2006) 1.16
Genetic and pharmacologic inhibition of mTORC1 promotes EMT by a TGF-β-independent mechanism. Cancer Res (2013) 1.07
Impaired autophagy due to constitutive mTOR activation sensitizes TSC2-null cells to cell death under stress. Autophagy (2011) 1.00
PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A (2013) 1.00
TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proc Natl Acad Sci U S A (2011) 0.98
Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis. Genes Chromosomes Cancer (2010) 0.97
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol (2014) 0.96
Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets (2007) 0.92
Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. Mol Cancer Ther (2011) 0.89
Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids (2011) 0.89
NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth. Cancer Lett (2015) 0.87
Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem (2012) 0.87
Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. FEBS Lett (2010) 0.83
A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival. J Biol Chem (2014) 0.83
Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention. Mol Pharm (2014) 0.80
Overexpression of phospho mutant forms of transglutaminase 2 downregulates epidermal growth factor receptor. Biochem Biophys Res Commun (2011) 0.80
Transglutaminase 2 in cancer. Am J Cancer Res (2015) 0.79
Silencing of TGM2 reverses epithelial to mesenchymal transition and modulates the chemosensitivity of breast cancer to docetaxel. Exp Ther Med (2015) 0.78